Breaking News

WuXi PharmaTech Completes Suzhou Biosafety Testing Facility

May 13, 2014

Expands platform of biologics services

WuXi PharmaTech has completed construction of its new biosafety testing facility in Suzhou. The facility has 38,000 sq.-ft. of labs and support areas, and is located next to WuXi's GLP preclinical drug safety facility. Operations will begin this summer, once validations are completed. Service offerings will include clinical and commercial lot release programs, viral clearance testing, and virus and molecular-based safety detection services for local and multinational customers.
 
"WuXi's expanding capabilities help our customers advance their biologic product candidates through development more quickly and cost-effectively," said Dr. Ge Li, chairman and chief executive officer of WuXi PharmaTech. "By investing in capabilities that address our customers' needs, we have become a leading biologics solution provider."
blog comments powered by Disqus
  • CMC Biologics: Growing Through Innovation

    Tim Wright, Editor||January 28, 2016
    The new chief exec talks about industry trends and growth plans.

  • Fit-For-Purpose Assay Development in Bioanalysis

    Fit-For-Purpose Assay Development in Bioanalysis

    Franklin Spriggs, Ligand Binding Assay Group Leader; Ashley Brant, Program Manager, AIT Bioscience||January 28, 2016
    The success of bioanalytical studies relies on the selection of the most suitable analytical method but the timeline of method development and types of analyses involved vary greatly.

  • Elemental Impurity Testing

    Elemental Impurity Testing

    Dr. Andrew Fussell, PANalytical ||January 28, 2016
    Advances in elemental impurity testing aid compliance with new USP requirements